LG Chem renews license triggering $2M payment to Avacta
South Korean clinical stage biopharmaceutical company, LG Chem Life Sciences, has triggered a license renewal…
Keep yourself up to date with the latest checkpoint inhibitor news. This section includes updates on clinical trials, approvals, collaboration deals, and technology advancements on checkpoint inhibitor therapy.
South Korean clinical stage biopharmaceutical company, LG Chem Life Sciences, has triggered a license renewal…
Domain Therapeutics, a biopharmaceutical company in France and Canada developing cancer immunotherapies targeting G protein-coupled…
Analysts are abuzz over GSK’s co-development deal with immuno-oncology specialist iTeos Therapeutics earlier this month,…
Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel…
The French company OSE Immunotherapeutics has signed a partnership to use artificial intelligence to develop…
A combination cancer immunotherapy from French biotech Innate Pharma was twice as effective at treating…
The US-UK biotech completed its $100M (€85M) IPO on the NASDAQ stock exchange to further…
Known for curing US President Jimmy Carter’s cancer, Keytruda continues to benefit many other cancer…
iTeos Therapeutics raised €65M ($75M) to bring two of its cancer treatments into the clinic…
Janssen will discontinue a Phase I study testing Danish biotech Genmab's blood cancer blockbuster daratumumab…
Checkpoint inhibitors, especially those targeting PD-1 and PD-L1, are exploding in popularity. But how much…
OSE Immunotherapeutics could receive up to €1.1Bn from its new partner Boehringer Ingelheim, which has…